BRPI0407596A - formulações orais semi-sólidas para liberação imediata compreendendo um agente anticáncer hidrofóbico, um glicerìdio poliglicolisado e veìculo hidrofìlico - Google Patents

formulações orais semi-sólidas para liberação imediata compreendendo um agente anticáncer hidrofóbico, um glicerìdio poliglicolisado e veìculo hidrofìlico

Info

Publication number
BRPI0407596A
BRPI0407596A BRPI0407596-0A BRPI0407596A BRPI0407596A BR PI0407596 A BRPI0407596 A BR PI0407596A BR PI0407596 A BRPI0407596 A BR PI0407596A BR PI0407596 A BRPI0407596 A BR PI0407596A
Authority
BR
Brazil
Prior art keywords
semi
immediate release
oral formulations
hydrophilic carrier
solid oral
Prior art date
Application number
BRPI0407596-0A
Other languages
English (en)
Inventor
Alessandro Martini
Cristina Ciocca
Paolo Gatti
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Publication of BRPI0407596A publication Critical patent/BRPI0407596A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"FORMULAçõES ORAIS SEMI-SóLIDAS PARA LIBERAçãO IMEDIATA COMPREENDENDO UM AGENTE ANTICáNCER HIDROFóBICO, UM GLICERìDEO POLIGLICOLISADO E VEìCULO HIDROFìLICO". A invenção presente diz respeito a uma composição farmacêutica adequada para administração por via oral, sob a forma de uma matriz semi-sólida, incluindo um ingrediente ativo pouco solúvel em água e presente em uma quantidade de entre 15% e 45%, por peso, da composição percentual farmacêutica; um agente tensoativo constituído por um glicerídeo poliglicolisado; e um veículo hidrofílico aceitável de um ponto de vista farmacêutico.
BRPI0407596-0A 2003-02-21 2004-01-30 formulações orais semi-sólidas para liberação imediata compreendendo um agente anticáncer hidrofóbico, um glicerìdio poliglicolisado e veìculo hidrofìlico BRPI0407596A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000074A ITRM20030074A1 (it) 2003-02-21 2003-02-21 Formulazioni semisolide a rilascio immediato intese
PCT/EP2004/050058 WO2004073592A2 (en) 2003-02-21 2004-01-30 Semi-solid immediate-release oral formulations comprising an anticancer hydrophobic agent, a polyglycolised glyceride and a hydrophilic carrier

Publications (1)

Publication Number Publication Date
BRPI0407596A true BRPI0407596A (pt) 2006-02-14

Family

ID=29765670

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0407596-0A BRPI0407596A (pt) 2003-02-21 2004-01-30 formulações orais semi-sólidas para liberação imediata compreendendo um agente anticáncer hidrofóbico, um glicerìdio poliglicolisado e veìculo hidrofìlico

Country Status (8)

Country Link
US (1) US20070141140A1 (pt)
EP (1) EP1596839A2 (pt)
JP (1) JP2006518353A (pt)
BR (1) BRPI0407596A (pt)
CA (1) CA2515887A1 (pt)
IT (1) ITRM20030074A1 (pt)
MX (1) MXPA05008921A (pt)
WO (1) WO2004073592A2 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2713112A1 (en) * 2008-02-13 2009-08-20 Ratiopharm Gmbh Pharmaceutical compositions comprising n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide
EP2113248A1 (en) * 2008-04-29 2009-11-04 Ratiopharm GmbH Pharmaceutical composition comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-,4-dimethyl-1H-pyrrole-3-carboxamide
EP2138167A1 (en) * 2008-06-24 2009-12-30 ratiopharm GmbH Pharmaceutical composition comprising N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
FR2967067A1 (fr) * 2010-11-10 2012-05-11 Sanofi Aventis Composition pharmaceutique et forme galenique a base de dronedarone et son procede de preparation
CA2942186C (en) * 2014-06-18 2023-06-27 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising non-ionic surfactants
WO2016020901A1 (en) 2014-08-07 2016-02-11 Acerta Pharma B.V. Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on btk occupancy and btk resynthesis rate

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5993858A (en) * 1996-06-14 1999-11-30 Port Systems L.L.C. Method and formulation for increasing the bioavailability of poorly water-soluble drugs
ATE554750T1 (de) * 1997-03-05 2012-05-15 Sugen Inc Hydrophobe pharmazeutische wirkstoffe enthaltende zubereitungen
FR2775188B1 (fr) * 1998-02-23 2001-03-09 Lipha Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption
GB9925127D0 (en) * 1999-10-22 1999-12-22 Pharmacia & Upjohn Spa Oral formulations for anti-tumor compounds
ATE290372T1 (de) * 2000-07-24 2005-03-15 Upjohn Co Selbstemulgierendes system zur abgabe von sehr wasserunlöslichen und lipophilen arzneimitteln

Also Published As

Publication number Publication date
WO2004073592A2 (en) 2004-09-02
ITRM20030074A1 (it) 2004-08-22
EP1596839A2 (en) 2005-11-23
ITRM20030074A0 (it) 2003-02-21
JP2006518353A (ja) 2006-08-10
US20070141140A1 (en) 2007-06-21
WO2004073592A3 (en) 2004-10-21
MXPA05008921A (es) 2005-10-05
CA2515887A1 (en) 2004-09-02

Similar Documents

Publication Publication Date Title
ES2557475T3 (es) Un portador que comprende uno o más derivados di- y/o monofosfato de agentes de transferencia de electrones
IL179718A0 (en) Pharmaceutical composition containing irbesartan
DK1553927T3 (da) Gel-stabiliserede, nanopartikulære aktivstof-sammensætninger
ES2194732T3 (es) Composiciones farmaceuticas orales de liberacion controlada de mesalazina.
BR9610424A (pt) Composições orais de rápida dissolução para agonistas da dopamina
PE20070377A1 (es) Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol
EP2246049A3 (en) Pharmaceutical composition and dosage forms for administration of hydrophobic drugs
WO2005063218A3 (en) Pharmaceutical formulations of bisphosphonates
WO2007048219A3 (en) Sustained drug release composition
HUP0301921A3 (en) Sustained release pharmaceutical compositions for paranteral administration of hydrophilic compounds
ES2422655T3 (es) Formulaciones de liberación inmediata potenciadas de topiramato
MY143549A (en) Compositions for external application, containing adenosyl cobalamin for improvement of skin diseases
WO2007017331A3 (en) Immediate release therapeutic systems for improved oral absorption of 7- [ (e) -tert-butyloxyiminomethyl] camptothecin
WO2006053089A3 (en) Methods and formulations for making pharmaceutical compositions containing bupropion
WO2006102533A3 (en) Pharmaceutically active lipid-based formulation of nucleoside-lipid conjugates
BRPI0407596A (pt) formulações orais semi-sólidas para liberação imediata compreendendo um agente anticáncer hidrofóbico, um glicerìdio poliglicolisado e veìculo hidrofìlico
CY1105168T1 (el) Διφασικη συνθεση με τραμαδολη
WO2005107702A3 (en) Sustained release, mucoadhesive vaginal pharmaceutical compositions
BRPI0412364A (pt) composição farmacêutica sólida, compreendendo amisulpride
WO2005115346A3 (en) Pharmaceutical composition containing risperidone
EE9700102A (et) Selegiliini sisaldav liposoomne kompositsioon
PE20050443A1 (es) Formulaciones farmaceuticas transdermicas
PE20050439A1 (es) Forma de dosificacion farmaceutica de liberacion prolongada
WO2003070155A3 (en) Orally administrable pharmaceutical formulation
BRPI0418427A (pt) formulações farmacêuticas de matriz semi-sólida

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.